PIN-5018 / Pin Therap - LARVOL DELTA

[ASCO 2025] Pin Therapeutics targets rare cancers with TPDs (Korea Biomedical Review) - "Pin Therapeutics evaluated the preclinical efficacy of its lead pipeline drug, PIN-5018, through this screening program....PIN-5018 is an orally administered CK1α-selective molecular glue degrader (MGD) that received phase 1 IND approval from the U.S. Food and Drug Administration (FDA) last month. The company plans to begin dosing the first patients in Korea for the phase 1a trial later this year....The promising preclinical data demonstrating PIN-5018 in the ACC PDX model provide new hope and valuable insights for the global ACC researcher and patient community."

Preclinical • Trial status • Adenoid Cystic Carcinoma

Pintherapeutics, CK1α Target Molecular Adhesion Degrader Receives FDA Phase 1 IND Approval [Google translation] (BioTimes) - "Domestic innovative new drug development company Pintherapeutics...announced on the 12th that it received approval for an investigational new drug (IND) plan from the US FDA last week for 'PIN-5018', a solid cancer treatment candidate based on a next-generation molecular glue degrader (MGD)....Phase 1a clinical trials are scheduled to begin in Korea in August-October 2025 for approximately 40 solid tumor patients, and initial results are expected before the second or third quarter of 2026."

IND • New P1 trial • Oncology • Solid Tumor

Next trip: a promising CK1α-selective molecular glue degrader in MSS colorectal cancer (AACR 2025) - "We recently developed PIN5018, a selective CK1α inhibitor, and reported that it exhibits promising anticancer activity in acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC)...Taken together, these findings demonstrate the potential of our CK1α-selective MGD as a promising therapeutic candidate not only for AML and ACC but also for MSS CRC. Lastly, we are aiming for clinical entry by 2025 Q1."

Acute Myelogenous Leukemia • Adenoid Cystic Carcinoma • Colorectal Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Pintherapeutics succeeds in raising 20 billion won in Series C amid bio-cold season [Google translation] (Hankyung) - "Pin Therapeutics, a protein degradation (TPD) drug development company, announced on the 23rd that it had attracted approximately KRW 20 billion in Series C investment....Through this investment, Pin Therapeutics plans to receive IND approval in the US and Korea in 2025 and advance its lead pipeline, a CK1α-selective degrader (PIN-5018), into the clinical stage. It also plans to discover additional next-generation pipelines based on platform technology."

Financing • IND • New trial • Oncology • Solid Tumor